Cullen/Frost Bankers heads into Q2 earnings season with a striking tension at its core: the stock is up 14% in a month, yet short sellers are piling in at the fastest pace in years while analysts are cutting their ratings.
The short interest buildup is the week's dominant data story. Short interest has climbed 58% over the past month, reaching 6.1% of free float — a level meaningful enough to demand attention. The weekly acceleration is particularly sharp, with shares short up 18% in just five sessions. Despite that, the borrow market remains loose. Availability of 505% means there are roughly five shares available to borrow for every one already out on loan, and cost to borrow has eased to 0.47%, down from 0.56% a month ago. That combination — rising short interest alongside cheap, plentiful borrow — tells you this is a deliberate directional bet, not a squeeze setup. The ORTEX short score confirmed the shift, climbing from around 48 ten days ago to 53.5 now, its highest reading in the recent window.
Options traders are leaning the opposite way, and that divergence is worth naming. The put/call ratio has dropped to 0.08, well below its 20-day average of 0.09 and near the bottom of the 52-week range. That puts the z-score at roughly -1.1 — options positioning is unusually call-heavy even as short sellers build. The two signals are pointing in opposite directions: bears borrowing shares, bulls buying calls. Neither has yet blinked.
The Street is tilting bearish heading into the July 30 results. Raymond James downgraded CFR to Market Perform from Outperform on July 1, the most significant recent move. Morgan Stanley maintained its Underweight rating while raising its target to $141, and Citigroup similarly held its Sell with a raised target of $145 — both firms lifting numbers grudgingly in recognition of the stock's run, but neither changing their negative stance. The mean price target sits at $153.67, fractionally below the current price of $154.52, which means the consensus effectively sees no upside from here. Valuation multiples have expanded materially: the P/E has expanded by 0.54 turns over the past month to 13.5x. The dividend score ranks in the 93rd percentile, a genuine positive, but the short score ranks in just the 8th percentile and the EPS 12-month forward growth rank sits at 27 — not the profile of a stock where the Street has conviction on near-term earnings acceleration.
The bull case rests on Texas-specific organic growth: branch expansion, loan and deposit momentum, and rising net interest income guidance. The bear case is concentrated risk — a pure Texas play vulnerable to any regional economic shock, with expenses running high and margins potentially under pressure as rate dynamics evolve. Close peers BOKF and CBSH gained around 2.7% and 3.2% respectively on the week, broadly in line with CFR's 3% gain, suggesting the regional bank group is moving together rather than the market making a CFR-specific call on price just yet.
Insider activity is thin and backward-looking. The most recent trade was a small $124k sale by the Chief Risk Officer in mid-June, with the prior cluster dated back to February. Nothing in the 90-day window signals conviction from management on either direction.
Q2 earnings on July 30 now frames everything — the last print delivered a -1.7% one-day move and a -3.0% five-day drift, and the question heading into the next release is whether the combination of a rising short base, a downgrade from Raymond James, and targets clustered below the current price reflects growing concern that the 14% rally has outrun the fundamentals.
See the live data behind this article on ORTEX.
Open CFR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
